The difference in tumor occurrence or spectrum resulting from MSH2 mutation carriers versus EPCAM deletion carriers may be related to the mosaic pattern of MSH2 inactivation displayed by EPCAM deletion carriers (8, 9). The gene discussed is EPCAM; the disease is neoplasm.